Keywords: BioMarin, Amifampridine, LEMS, EU approval,

BioMarin’s amifampridine phosphate gets EU marketing approval for LEMS

Article | 6 January 2010

The European Commission has granted marketing approval for US drugmaker BioMarin Pharmaceutical’s 3,4-diaminopyridine (amifampridine phosphate), for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).

Amifampridine phosphate, developed by the pharmaceutical unit of France’s Paris Public Hospital Authority (AP-HP) and licensed from EUSA Pharma SAS, is the first approved treatment for LEMS, thereby conferring orphan drug protection and providing 10 years of market exclusivity in Europe. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.

FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!

Sign up in less than 60 seconds...no payment needed

Want to read the full article?
Take a 30 day FREE Trial worth £60

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in